Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Rab 32 Gene Polymorphisms as a Prognostic Factor in Leprosy Patients — Stella

Home/Leprosy/Rab 32 Gene Polymorphisms as a Prognostic Factor in Leprosy Patients

View on ClinicalTrials.gov

Recruiting

Back to Leprosy trials

Rab 32 Gene Polymorphisms as a Prognostic Factor in Leprosy Patients

Not a traditional drug trial — this study doesn't follow the standard phase structure.

Trial locations(1 site)

Egypt

Qina University hospital, South Valley University Hospital, Qina

Key details

Sponsor

South Valley University

Enrollment target

~50 participants

Started

December 2024

Primary completion

December 2025

This trial's estimated completion date has passed — the record may not be fully up to date.

Age range

5 Years – 60 Years

Last updated February 2025

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.